Loading patent…
AssigneesVisterra, Inc., Duke University
InventorsDavid William Oldach, Stuart Johnston Knechtle, Gregory Babcock, John J. O'Neil, Jean Kwun
Estimating the term…
The present invention provides, among other things, a method of prophylaxis for kidney rejection comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant. In another aspect, the present invention provides, among other things, a method of improving a kidney transplant in a recipient, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplantation at a therapeutically effective amount, wherein the improvement in the kidney transplant results in prolonged stability of the kidney transplant, survival of the recipient, and/or reduced rejection symptoms as compared to a control.
A method of prophylaxis for kidney rejection in a recipient receiving a kidney transplant, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant.
A method of improving a kidney transplant in a recipient,
4-10. (canceled)
A method of conditioning a kidney transplant recipient,
16-20. (canceled)
(canceled)
27-28. (canceled)
(canceled)
(canceled)
35-47. (canceled)
49-54. (canceled)
A method of prophylaxis for kidney rejection in a recipient receiving a kidney transplant, comprising administering to the recipient an IL-2 variant in conjunction with the kidney transplant, wherein the IL-2 variant comprises one or more amino acid substitutions selected from Table 1.
56-60. (canceled)
62-72. (canceled)
Dependencies are inferred from the claim text.